Avantogen to co-develop genital herpes vaccine
08 June, 2005 by Ruth BeranAvantogen (ASX:ACU), formerly known as Australian Cancer Tehcnology, is to team up with the University of Alabama at Birmingham (UAB) to conduct a preclinical study to develop a new therapeutic vaccine for herpes simplex virus type 2 (HSV-2).
How microbial screening is uncovering buried treasure
03 June, 2005 by Graeme O'NeillGenome scientist Craig Venter is cruising the world in his yacht, sampling the genetic diversity of marine bacteria and microbes wafted over the oceans by intercontinental winds, and finding enough genetic treasure to keep drug-hunters in work for a few centuries.
TGA approves VacTX vaccine trials
26 May, 2005 by Graeme O'NeillAustralia's Therapeutic Goods Administration (TGA) has approved a clinical trial of a new immunotherapeutic vaccine for chronic hepatitis C infection, developed by VacTX, a joint venture between EqiTX (ASX:EQX) and the CRC for Vaccine Technology
Living Cell Technologies finalises technology acquisition
19 May, 2005 by Graeme O'NeillAuckland-based cell therapy company Living Cell Technologies (ASX:LCT) will hold a general meeting next week to formally seal a deal under which it has acquired technology and IP worth US$90 million from with US cell-therapy company Theracyte.
IMB team first to ID endocytosis mechanism
19 May, 2005 by Graeme O'NeillElectron microscopists at the University of Queensland's Institute for Molecular Bioscience have spotted the first, sub-microscopic components of the molecular machinery of endocytosis -- the process by which living cells take up nutrients and particles.
Florey director reflects on a revolution in neuroscience
16 May, 2005 by Graeme O'NeillEminent Melbourne neuroscientist Prof Fred Meldelsohn, director of Melbourne's Howard Florey Institute, is the Bethlehem Griffiths Research Foundation medallist for 2005.
Phylogica gets IP boost
02 May, 2005 by Graeme O'NeillThe US Patent Office has granted Perth biotech Phylogica's application for a patent on its technology for isolating biological modulators from its burgeoning library of gene fragments from "extremophile" microbes.
Sydney researchers zero in on stem cells
13 April, 2005 by Susan WilliamsonResearchers at the Diabetes Transplant Unit at the Prince of Wales Hospital in Sydney have developed a new technique for extracting single human embryonic stem (ES) cells, bringing them one step closer to harnessing the therapeutic potential of stem cells.
The near-term potential of stem cell therapies
08 April, 2005 by Silviu ItescuThe prospect of therapies based on human stem cells holds great promise for revolutionising the practice of medicine, says Silviu Itescu.
The commercial value and business of human ES cells
08 April, 2005 by Peter Mountford and Kenzo NakajimaThe human embryonic stem (ES) cell field is one of the most exciting and complex opportunities of today's biomedical industry, write Peter Mountford and Kenzo Nakajima.
Stem cells: Researchers warn of lost ground
06 April, 2005 by Melissa TrudingerSome of Australia's most eminent researchers have warned that Australia must get creative to stay on top in the increasingly competitive global stem cell research and business landscape.
The hard cell: research debate to fire up again
06 April, 2005 by Melissa TrudingerMelissa Trudinger looks at the issues that are set to arise as debate begins again on stem cell research in Australia.
Neuroscience in the future
05 April, 2005 by Susan WilliamsonMax Bennett spoke with Susan Williamson about what's in store for neuroscience in coming years.
The hard cell
04 April, 2005 by Melissa TrudingerAdvocates and opponents of stem cell research across Australia are gearing up for the reignition of the debate that polarised Australia's state and federal governments in 2002.
Mosquito-borne virus helps in vaccine vector quest
04 April, 2005 by Graeme O'NeillA new Brisbane biotech, RepliKun, has been spun out from the Queensland Institute of Medical Research (QIMR), the University of Queensland and the state's health department to commercialise a novel vaccine vector, based on the Kunjin virus replicon -- the self-replicating genetic core of the mosquito-borne virus of Australia's tropics.
